论文部分内容阅读
目前,直接PCI已经成为急性ST段抬高心肌梗死(STEMI)的优选治疗方法。然而,由于直接PCI术中“无复流现象”的大量出现,已成为PCI预后及心脏事件的独立危险因素。随着血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班在无复流现象中的应用,它在治疗无复流现象的作用越来越受到重视,但由于临床医师过度担心替罗非班可能会增加老年患者出血的风险,故在老年患者中的应用较少。替罗非班的常规应用方法为静脉注射后,静脉维持。本研究采用冠状动脉内直接注射替罗非班后常规静脉半量维持的方法治疗老年STEMI患者PCI术中出现无复流现象后的处理,旨在探讨冠状动脉内注射替罗非班在治疗老年STEMI患
Currently, direct PCI has become the preferred treatment for acute ST-segment elevation myocardial infarction (STEMI). However, due to the large number of “no-reflow phenomenon” in direct PCI, it has become an independent risk factor for PCI prognosis and cardiac events. With the application of platelet glycoprotein Ⅱb / Ⅲa receptor antagonist tirofiban in the no-reflow phenomenon, its role in the treatment of no-reflow phenomenon has drawn more and more attention. However, as clinicians over-worry about tirofiban Classes may increase the risk of bleeding in elderly patients and are therefore less commonly used in elderly patients. Tirofiban routine use of intravenous injection method, the vein to maintain. In this study, the direct intracoronary injection of tirofiban routine venous half-dose maintenance treatment of elderly patients with STEMI after PCI no-reflow phenomenon after the treatment to explore the intracoronary injection of tirofiban in the treatment of elderly STEMI Suffering